Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07698106 | Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC | not yet recruiting | Phase 1 / Phase 2 | 60 | University Health Network, TorontoOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07838649 | Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity | not yet recruiting | Phase 1 | 36 | Washington University School of MedicineOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 106 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | not yet recruiting | Phase 1 | 285 | Sutro Biopharma, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07300475 | Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients | not yet recruiting | Phase 1 | 30 | Washington University School of MedicineOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04430595 | Multi-4SCAR-T Therapy Targeting Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07596212 | BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder | not yet recruiting | Phase 1 / Phase 2 | 100 | University of Illinois at ChicagoOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07553390 | Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers | not yet recruiting | Phase 1 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07774624 | Study of SKB103 in HER2-negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 140 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 0 | Aug 19, 2026 | clinicaltrials |
| NCT07272642 | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.(DUNP19) | not yet recruiting | Phase 1 | 16 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07738341 | GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ) | not yet recruiting | Phase 1 / Phase 2 | 270 | Eddingpharm (Zhuhai) Co., Ltd.INDUSTRY | 0 | Jul 31, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07697443 | Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects | not yet recruiting | Phase 1 / Phase 2 | 306 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07681297 | Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease(TIBEC) | not yet recruiting | Phase 1 / Phase 2 | 154 | National University Hospital, SingaporeOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07217990 | Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer(NoCUT-BC) | not yet recruiting | Phase 1 / Phase 2 | 84 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07581314 | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) | not yet recruiting | Phase 1 / Phase 2 | 76 | Telomir Pharmaceuticals, Inc.INDUSTRY | 0 | Jun 23, 2026 | clinicaltrials |
| NCT07590583 | Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE Trial | not yet recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07580833 | A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 46 | Health Hope PharmaINDUSTRY | 0 | May 12, 2026 | clinicaltrials |
| NCT07560124 | A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 286 | AkesoINDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07494448 | Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer(JAZMINE) | not yet recruiting | Phase 1 / Phase 2 | 24 | MedSIROTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT02802423 | Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. | not yet recruiting | Phase 1 / Phase 2 | 44 | BioLite, Inc.INDUSTRY | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07454668 | Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases | not yet recruiting | Phase 1 | 20 | Baptist Health South FloridaOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07423117 | A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy | not yet recruiting | Phase 1 | 102 | IntoCell, IncINDUSTRY | 0 | Feb 20, 2026 | clinicaltrials |
| NCT07370506 | Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 36 | Tanta UniversityOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07336771 | JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 60 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07292142 | FMT in Triple Negative Breast Cancer Guided by ctDNA(FRIDA) | not yet recruiting | Phase 1 / Phase 2 | 125 | Jewish General HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07260058 | Immune Cell Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 48 | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.INDUSTRY | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07189884 | Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy | not yet recruiting | Phase 1 / Phase 2 | 33 | The First Affiliated Hospital of Xiamen UniversityOTHER | 0 | Sep 24, 2025 | clinicaltrials |
| NCT07177950 | A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases | not yet recruiting | Phase 1 / Phase 2 | 51 | Peking University Cancer Hospital & InstituteOTHER | 0 | Sep 17, 2025 | clinicaltrials |
| NCT07173556 | A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 96 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 15, 2025 | clinicaltrials |
| NCT05806385 | Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers(LOGIC) | not yet recruiting | Phase 1 / Phase 2 | 36 | Texas Tech University Health Sciences CenterOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT07161791 | Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 12 | Harbin Medical UniversityOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT07139470 | Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 59 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07088588 | Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors | not yet recruiting | Phase 1 | 105 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 28, 2025 | clinicaltrials |
| NCT07067307 | Melatonin in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07036185 | A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors | not yet recruiting | Phase 1 | 66 | Shanghai Bao Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06948539 | To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors | not yet recruiting | Phase 1 | 66 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06941142 | A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer | not yet recruiting | Phase 1 | 382 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Apr 23, 2025 | clinicaltrials |
| NCT06788197 | A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 52 | Henan Cancer HospitalOTHER_GOV | 0 | Mar 26, 2025 | clinicaltrials |
| NCT06775236 | Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 410 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT05821686 | Efficacy of Interleukin-2 in Triple Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 10 | Nova Scotia Health AuthorityOTHER | 0 | Feb 12, 2025 | clinicaltrials |
| NCT06757335 | A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 204 | Hinova Pharmaceuticals Inc.INDUSTRY | 0 | Jan 3, 2025 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06531486 | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 96 | NovaOnco Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 1, 2024 | clinicaltrials |
| NCT05986071 | I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers(MATRIX) | not yet recruiting | Phase 1 / Phase 2 | 57 | Institut Paoli-CalmettesOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT06023277 | A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 40 | Jacinto Convit World Organization Inc.OTHER | 2 | Sep 5, 2023 | clinicaltrials |
| NCT05519670 | A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr(CAPRICE) | not yet recruiting | Phase 1 / Phase 2 | 72 | Institut Paoli-CalmettesOTHER | 0 | Aug 29, 2022 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials